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Introduction 
 
On October 6, 2006, the U.S. Food and Drug Administration 
granted approval to vorinostat (Zolinza), a histone deacetylase 
inhibitor, for the treatment of cutaneous manifestations of 
cutaneous T-cell lymphoma (CTCL) in patients with progressive, 
persistent, or recurrent disease on or following two systemic 
therapies. 
 
Interaction with target 
 
Vorinostat binds to the active site of the class I and IIa HDACs, 
inhibiting its activity. 
 
IC50 < 86 nM 
 
Figure 1. Image of the interactions  
Between vorinostat and its target. (1) 
 
Adverse effects 
 
Vorinostat  presents mild adverse effects: 
 
  diarrhea, vomiting, thrombocytopenia and dehydration. 
 
Epithelial-mesenchymal transition and 
metastasis 
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Figure 2. Image of K7M2 tumoral cell line culture with and without vorinostat. (2) 
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Efficacy 
 
The major trial supporting approval was a single-arm open-label 
trial  that enrolled 74 patients with stage IB and higher CTCL who 
had failed two systemic therapies.  In this study, 30% experienced 
responses. Vorinostat shows promising effectiveness in 
combination with other therapies. 
 
  Figure 3. Toracic cavity 
  scanner of a pacient with 
  Hodkin’s limphome before 
  and after vorinostat  
  treatment. (3) 
 
 
Conclusions 
 
  Vorinostat is able to stop the metastasis 
through the inhibition of HDACs. 
 
  Vorinostat is able to inhibit EMT stopping 
cancer progression. 
 
  Vorinostat action mechanism is very complex 
and  involves several signalling pathways. 
 
  Vorinostat may be a good candidate as an 
anticancer drug. 
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